Roloff Tom, Haussleiter Ida, Meister Klara, Juckel Georg
Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr University Bochum, Alexandrinenstr. 1, 44791, Bochum, Germany.
Int J Bipolar Disord. 2022 Mar 1;10(1):6. doi: 10.1186/s40345-022-00254-8.
Sleep dysfunction is a core symptom in bipolar disorder (BD), especially during major mood episodes. This study investigated the possible link between subjective and objective sleep disturbances in inter-episode BD, changes in melatonin and cortisol levels, and circadian melatonin alignment. The study included 21 euthymic BD patients and 24 healthy controls. Participants had to wear an actigraphy device, keep a weekly sleep diary and take salivary samples: five samples on the last evening to determine the dim light melatonin onset (DLMO) and one the following morning to measure rising cortisol. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI) and Regensburg Insomnia Scale (RIS), and circadian alignment by the phase angle difference (PAD).
In comparison to healthy controls, BD patients had: (1) higher PSQI (5.52 ± 3.14 vs. 3.63 ± 2.18; p = 0.022) (significant after controlling for age and gender), and higher RIS scores (8.91 ± 5.43 vs. 5.83 ± 3.76; p = 0.031); (2) subjective a longer mean TST (p = 0.024) and TIB (p = 0.002) (both significant after controlling for age and gender), longer WASO (p = 0.019), and worse SE (p = 0.036) (significant after controlling for gender); (3) actigraphically validated earlier sleep onset (p = 0.002), less variation in sleep onset time (p = 0.005) and no longer TST (p = 0.176); (4) no differing melatonin levels (4.06 ± 2.77 vs. 3.35 ± 2.23 p = 0.352), an 1.65 h earlier DLMO (20.17 ± 1.63 vs. 21.82 ± 1.50; p = 0. 001) (significant after controlling for gender), and a phase advance of melatonin (6.35 ± 1.40 vs. 7.48 ± 1.53; p = 0.017) (significant after controlling for gender); and (5) no differing cortisol awakening response (16.97 ± 10.22 vs 17.06 ± 5.37 p = 0.969).
Patients with BD, even in euthymic phase, have a significantly worse perception of their sleep. Advanced sleep phases in BD might be worth further investigation and could help to explain the therapeutic effects of mood stabilizers such as lithium and valproate.
睡眠功能障碍是双相情感障碍(BD)的核心症状,尤其是在主要情绪发作期间。本研究调查了BD发作间期主观和客观睡眠障碍之间的可能联系、褪黑素和皮质醇水平的变化以及昼夜褪黑素的一致性。该研究纳入了21名病情缓解期的BD患者和24名健康对照者。参与者必须佩戴活动记录仪,每周记睡眠日记并采集唾液样本:在最后一个晚上采集5份样本以确定暗光褪黑素起始时间(DLMO),在第二天早晨采集1份样本以测量皮质醇升高情况。通过匹兹堡睡眠质量指数(PSQI)和雷根斯堡失眠量表(RIS)评估睡眠质量,通过相位角差(PAD)评估昼夜一致性。
与健康对照者相比,BD患者:(1)PSQI更高(5.52±3.14对3.63±2.18;p = 0.022)(在控制年龄和性别后具有统计学意义),且RIS得分更高(8.91±5.43对5.83±3.76;p = 0.031);(2)主观上平均总睡眠时间(TST)更长(p = 0.024)和卧床时间(TIB)更长(p = 0.002)(在控制年龄和性别后均具有统计学意义),清醒时间(WASO)更长(p = 0.019),睡眠效率(SE)更差(p = 0.036)(在控制性别后具有统计学意义);(3)经活动记录仪验证入睡时间更早(p = 0.002),入睡时间变化更小(p = 0.005),TST无差异(p = 0.176);(4)褪黑素水平无差异(4.06±2.77对3.35±2.23,p = 0.352),DLMO提前1.65小时(20.17±1.63对21.82±1.50;p = 0.001)(在控制性别后具有统计学意义),且褪黑素相位提前(6.35±1.40对7.48±1.53;p = 0.017)(在控制性别后具有统计学意义);(5)皮质醇觉醒反应无差异(16.97±10.22对17.06±5.37,p = 0.969)。
BD患者即使在病情缓解期,对其睡眠的感知也明显更差。BD患者的睡眠阶段提前可能值得进一步研究,并且有助于解释锂盐和丙戊酸盐等心境稳定剂的治疗效果。